Your browser doesn't support javascript.
loading
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes.
Cecchini, Michael; Walther, Zenta; Sklar, Jeffrey L; Bindra, Ranjit S; Petrylak, Daniel P; Eder, Joseph P; Goldberg, Sarah B.
Affiliation
  • Cecchini M; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
  • Walther Z; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
  • Sklar JL; Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
  • Bindra RS; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA.
  • Petrylak DP; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
  • Eder JP; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
  • Goldberg SB; Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA. Electronic address: sarah.goldberg@yale.edu.
Lancet Oncol ; 19(1): 23-24, 2018 01.
Article in En | MEDLINE | ID: mdl-29304353
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phthalazines / Piperazines / Prostatic Neoplasms / Sarcoma / Molecular Targeted Therapy / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Phthalazines / Piperazines / Prostatic Neoplasms / Sarcoma / Molecular Targeted Therapy / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Prognostic_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article Affiliation country: United States